RESEARCH TRIANGLE PARK, N.C., Sept. 2 NovaQuest, themanaged partnership group of Quintiles Transnational Corp., has received EliLilly and Company's highest award for its "flawless execution" over four yearsin helping Lilly achieve strategic and operational objectives vital to itsbusiness success.
In honoring NovaQuest with its "2008 Lilly Global Sustained SupplierAward," Lilly cited NovaQuest's ability to create, manage and executestrategic partnerships that have helped Lilly meet critical corporatepriorities. Lilly CEO John Lechleiter presented the award to NovaQuestPresident Ron Wooten.
"We are proud to have received this award, which recognizes the ongoingsuccess Lilly and NovaQuest have achieved since our initial partnership in2004 to co-promote Cymbalta(R), Lilly's blockbuster treatment for depression,in the United States," said Wooten, who also is Executive Vice President ofQuintiles Transnational.
"Success breeds trust, and we are proud of our role in helping Lillytransform its business model to deliver better patient outcomes. We lookforward to continued mutually beneficial successes in both commercializationand development."
NovaQuest is the partner of choice for pharmaceutical and biotechnologycompanies seeking to overcome challenges stifling their product development,commercialization and financial goals. The managed partnership group ofQuintiles Transnational, NovaQuest uniquely offers accelerated pipelinedevelopment, flexible resourcing, new capital streams and access tosenior-level expertise. Since 2000, NovaQuest has created more than 80 managedpartnerships with $2.7 billion committed to helping its partners acceleratetheir strategy and transform their businesses to reach new heights of success.For more information, please visit www.novaquest.com